– FRANCE, Nantes – OSE Immunotherapeutics SA (EPA: OSE) today announced the appointment of Dr. Alexandre Lebeaut (M.D.) to its Board as an Independent Director, replacing Alexis Peyroles who resigned from the Board.
“We are very pleased to welcome Alexandre who brings an extensive American and international experience and leadership in R&D strategic positions, and particularly in immunology. His recognized expertise is in match with the Company’s new phase of growth focused on advancing our preclinical and clinical diversified first-in-class portfolio in immuno-oncology and immunology & inflammation”, said CEO, Dominique Costantini.
About Dr. Alexandre Lebeaut
Alexandre Lebeaut has more than 25 years of valuable experience and leadership both in innovation, research, and development, from preclinical to the post-marketing stage and with major achievements in particular in immunology, oncology, immuno-inflammation, and infectious diseases. He has held various global positions, notably in the United States at Bluebird Bio, Sanofi, Novartis, and Schering Plough Research Institute. Most recently, Alexandre Lebeaut served as EVP R&D and CSO at Ipsen in the US. He currently heads “I-ACT for Children” (Institute for Advanced Clinical Trials), an American non-profit organization based in Maryland which is dedicated to pediatric drug development.
Alexandre Lebeaut said: “I am honored to be joining OSE’s Board and I thank the Directors for their confidence. Along with the management team, I will be happy to contribute to the Company’s growth in this critical phase of its transformation by further establishing OSE as a recognized leader in immunotherapy and by enlarging its global visibility”.”
Alexandre is a French and US citizen and is a Doctor of Medicine (University of Paris Diderot Paris VII) and a pediatrician (University of Paris Descartes).
About OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
For more information: https://www.ose-immuno.com/en/home/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
